ERBB2 and gastric cancer: Although there is currently no consensus on the relationship between HER2 amplification and patient prognosis in gastric cancer (Janjigian et al., 2012; Gómez-Martin et al., 2012; Begnami et al., 2011; Kim et al., 2011), our analysis of multiple GEO datasets suggests that HER2 amplification is associated with shortened patient survival (Figure 4F).